Novartis' Radioligand Therapies Pipeline and Strategic Acquisitions: Key Drivers Behind Radioligand Therapies Market Exponential Growth Through 2034 | DelveInsight

The radioligand therapies market is experiencing remarkable expansion through 2034. Novartis has emerged as the market leader in this landscape, with PLUVICTO and LUTATHERA capturing the largest market share. Radioligand Therapies represent a major advancement in precision oncology, with increasing adoption for both approved indications and extensive research into new therapeutic applications positioning them as one of the fastest-growing segments in targeted cancer treatment.
DelveInsight's report, "Radioligand Therapies Market Size, Target Population, Competitive Landscape & Market Forecast - 2034 [https://www.delveinsight.com/report-store/radioligand-therapies-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]", provides in-depth analysis of radioligand therapies market dynamics, epidemiology trends, and emerging technologies that will shape the future of radioligand therapies, which is transforming cancer treatment paradigms across multiple oncology indications.

Radioligand therapy works through a sophisticated mechanism that delivers targeted radiation directly to tumor sites. The process begins by identifying specific proteins overexpressed on cancer cell surfaces, then developing targeting molecules (ligands) attached to radioactive isotopes. These are administered intravenously and bind to target proteins on cancer cells, delivering localized radiation that damages the DNA of cancer cells while minimizing exposure to healthy tissues. Therapeutic radioisotopes are produced in special nuclear reactors or generators, then shipped to production facilities where they are bonded to cell-targeting compounds, creating ready-to-use therapies that can be administered in hospital or clinic settings.

The radioligand therapy landscape has seen substantial clinical progress since 2018, when the FDA approved LUTATHERA, manufactured by Novartis, as the first radiopharmaceutical for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). LUTATHERA's success has been remarkable, with sales exceeding USD 450 million in the first nine months of 2023 alone, representing a 34% year-over-year growth.

Stay informed on the latest FDA approvals @ Radioligand Therapies FDA Approvals [https://www.delveinsight.com/sample-request/radioligand-therapies-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

Novartis projects peak sales could surpass USD 1 billion as it expands into first-line therapy. In a significant milestone for pediatric oncology, LUTATHERA received FDA approval in 2024 as the first medicine specifically for pediatric patients with GEP-NETs, broadening its therapeutic reach to younger patient populations with these rare tumors.

The market's expansion accelerated in 2022 with the FDA's approval of PLUVICTO (lutetium Lu 177 vipivotide tetraxetan), also developed by Novartis (SWX: NOVN), for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) in patients who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy. PLUVICTO demonstrated impressive commercial performance, generating approximately USD 980 million in sales during its first full year, narrowly missing blockbuster status.

Explore ongoing and upcoming clinical trials driving innovation in radioligand therapies @ Radioligand Therapies Clinical Trials [https://www.delveinsight.com/sample-request/radioligand-therapies-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]

Other established radioligand therapies include Bayer's XOFIGO (radium ra-223 dichloride) for castration-resistant prostate cancer with symptomatic bone metastases, and Spectrum Pharmaceuticals' ZEVALIN (ibritumomab tiuxetan) for relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma.

The industry has witnessed significant strategic movements throughout 2023-2024, highlighting the growing importance of radioligand therapies in oncology portfolios. In March 2024, AstraZeneca (LON: AZN) acquired Fusion Pharmaceuticals (NASDAQ: FUSN) for USD 2 billion to accelerate the development of next-generation radioconjugates, bringing new expertise and pioneering R&D in actinium-based radioconjugates to enhance their cancer treatment pipeline. Furthermore, in May 2024, Novartis acquired Mariana Oncology, a cancer RLT-focused biotech, for USD 1 billion upfront with potential additional payments of up to USD 750 million upon milestone completion.

In December 2023, Eli Lilly completed its acquisition of Point Biopharma for approximately USD 1.4 billion, gaining ownership of Point's lead asset PNT2002, a radioligand therapy targeting PSMA for metastatic castration-resistant prostate cancer. Additionally, January 2024 saw two significant operational developments: the FDA's approval of Novartis's new automated radioligand therapy production plant for PLUVICTO, and InHealth's launch of the UK's first relocatable radioligand therapy service, enhancing treatment accessibility.

Discover evolving trends in the radioligand therapies landscape @ Radioligand Therapies Recent Developments [https://www.delveinsight.com/sample-request/radioligand-therapies-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

The radioligand therapy pipeline continues to expand with several promising candidates advancing through clinical development. Curium US (NASDAQ: CURI) is developing 177Lu-PSMA-I&T, currently in phase III ECLIPSE trial (NCT05146973), which targets prostate-specific membrane antigen. Eli Lilly (NYSE: LLY) and Point Biopharma (NASDAQ: PNT) are advancing Lu-PNT2002, a PSMA-targeted lutetium-177-based radioligand therapy currently in phase III SPLASH trial (NCT04647526) combines PSMA-I&T with the beta-emitting radioisotope no-carrier-added lutetium-177.

Other pipeline candidates include Fusion Pharmaceuticals' FPI-2265 in Phase II/III studies, Lantheus (NASDAQ: LNTH) and Eli Lilly's LNTH-1095, Novartis's 225Ac-PSMA-R2, and Bayer's 225Ac-PSMATrillium, all targeting various stages of prostate cancer and poised to expand treatment options in the coming years.

The market's growth trajectory is supported by increasing cancer diagnosis rates, growing awareness of radioligand therapy's benefits, expanding clinical trial activity, and major pharmaceutical companies' increasing interest in this therapeutic space. With Novartis already having two RLTs available globally, numerous candidates in its pipeline, and several clinical trials underway or planned, the radioligand therapy market is positioned for sustained expansion.

Download the Radioligand Therapy Market Forecast Report to understand which factors are driving the Radioligand Therapy market @ Radioligand Therapy Market Trends [https://www.delveinsight.com/sample-request/radioligand-therapies-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

As more data becomes available from ongoing clinical trials and new applications are discovered for conditions beyond the current indications of neuroendocrine tumors and prostate cancer, radioligand therapy is expected to become an increasingly integral component of cancer treatment protocols, further driving market growth and improving outcomes for patients with difficult-to-treat malignancies across the 7MM.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of Radioligand Therapies

4. Key Events

5. Radioligand Therapies Market Overview At A Glance

6. Background And Overview

7. Target Population

8. Radioligand Therapies Marketed Drugs

9. Radioligand Therapies Emerging Drugs

10. Radioligand Therapies: The 7MM Analysis

11. Radioligand Therapy Unmet Needs

12. SWOT Analysis

13. KOL Views

14. Radioligand Therapy Market Access and Reimbursement

15. Appendix

16. Delveinsight Capabilities

17. Disclaimer

18. About DelveInsight

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=novartis-radioligand-therapies-pipeline-and-strategic-acquisitions-key-drivers-behind-radioligand-therapies-market-exponential-growth-through-2034-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.